钠-葡萄糖协同转运蛋白2抑制剂与膀胱癌短期风险:一项国际多中心队列研究
该多中心、基于人群的新使用者活性对照队列研究纳入2型糖尿病成人,比较SGLT2抑制剂与GLP-1受体激动剂或DPP-4抑制剂的膀胱癌发生风险。结果显示,SGLT2抑制剂与GLP-1受体激动剂相比(HR 0.90,95%CI 0.81-1.00)或与DPP-4抑制剂相比(HR 0.99,95%CI 0.91-1.09),均未与膀胱癌风险增加相关。
要点
- 与GLP-1受体激动剂相比,SGLT2抑制剂未增加膀胱癌风险(HR 0.90,95%CI 0.81-1.00)。
- 与DPP-4抑制剂相比,SGLT2抑制剂未增加膀胱癌风险(HR 0.99,95%CI 0.91-1.09)。
- 敏感性分析结果一致,为SGLT2抑制剂短期膀胱癌影响提供 reassurance。
核心结论
- 与既往随机对照试验相反,这些发现表明,与GLP-1受体激动剂或DPP-4抑制剂相比,使用SGLT2抑制剂与膀胱癌风险增加无关。
- 这应能为SGLT2抑制剂对膀胱癌发病率的短期影响提供 reassurance。
研究设计与样本
- 多中心、基于人群、新使用者、活性对照队列研究,使用英国临床实践研究数据链、Medicare fee-for-service、Optum去标识化Clinformatics Data Mart数据库和MarketScan健康数据库,时间范围为2013年1月至2020年12月。
- 组建两个2型糖尿病成人队列:1)启动SGLT2抑制剂或GLP-1受体激动剂;2)启动SGLT2抑制剂或DPP-4抑制剂。
- 采用Cox比例风险模型估计膀胱癌发病的风险比(HR)和95%CI,模型使用倾向评分精细分层加权,各中心HR采用随机效应模型合并。
主要发现
- SGLT2抑制剂使用者(n=453,560)和GLP-1受体激动剂使用者(n=375,997)的中位随访时间为1.5至2.2年。
- 总体而言,与GLP-1受体激动剂相比,SGLT2抑制剂与膀胱癌风险增加无关(HR 0.90,95%CI 0.81-1.00)。
- 与DPP-4抑制剂(n=853,186)相比,SGLT2抑制剂(n=347,059)在中位随访1.6至2.6年期间与膀胱癌风险增加无关(HR 0.99,95%CI 0.91-1.09)。
- 敏感性分析结果一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether sodium-glucose cotransporter 2 (SGLT2) inhibitors, compared with glucagon-like peptide 1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase 4 (DPP-4) inhibitors, are associated with an increased risk of early bladder cancer events. RESEARCH DESIGN AND METHODS: We conducted a multisite, population-based, new-user, active comparator cohort study using the U.K. Clinical Practice Research Datalink, Medicare fee-for-service, Optum's de-identifed Clinformatics Data Mart Database (CDM), and MarketScan Health databases from January 2013 through December 2020. We assembled two cohorts of adults with type 2 diabetes initiating 1) SGLT2 inhibitors or GLP-1RAs and 2) SGLT2 inhibitors or DPP-4 inhibitors. Cox proportional hazards models were fit to estimate hazard ratios (HRs) and 95% CIs of incident bladder cancer. The models were weighted using propensity score fine stratification. Site-specific HRs were pooled using random-effects models. RESULTS: SGLT2 inhibitor (n = 453,560) and GLP-1RA (n = 375,997) users had a median follow-up ranging from 1.5 to 2.2 years. Overall, SGLT2 inhibitors were not associated with an increased risk of bladder cancer compared with GLP-1RAs (HR 0.90, 95% CI 0.81-1.00). Similarly, when compared with DPP-4 inhibitors (n = 853,186), SGLT2 inhibitors (n = 347,059) were not associated with an increased risk of bladder cancer (HR 0.99, 95% CI 0.91-1.09) over a median follow-up ranging from 1.6 to 2.6 years. Results were consistent across sensitivity analyses. CONCLUSIONS: Contrary to previous randomized controlled trials, these findings indicate that the use of SGLT2 inhibitors is not associated with an increased risk of bladder cancer compared with GLP-1RAs or DPP-4 inhibitors. This should provide reassurance on the short-term effects of SGLT2 inhibitors on bladder cancer incidence.
引用
- Abrahami D, Tesfaye H, Yin H, et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. 2022. PMID: 36170656. doi:10.2337/dc22-1174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。